Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock Performance - Merck (MRK) closed at $98 37, reflecting a -1 33$7 72 per share, marking a +411 26% change from last year [4] - Full-year revenue is anticipated to be $64 06 billion, a +6 56$1 80, a 5900% rise compared to the same quarter of the previous year [8] - Quarterly revenue is estimated at $15 52 billion, up 6 05% from the year-ago period [8] Valuation Metrics - Merck has a Forward P/E ratio of 12 91, denoting a discount relative to the industry's average Forward P/E of 13 88 [9] - The company holds a PEG ratio of 1 43, slightly below the Large Cap Pharmaceuticals industry average of 1 46 [7] Industry and Sector Analysis - The Large Cap Pharmaceuticals industry is part of the Medical sector and ranks 141 out of over 250 industries, placing it in the bottom 44% [11] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [10] Analyst Revisions and Rankings - The Zacks Consensus EPS estimate has moved 0 04% lower within the past month [6] - Merck currently holds a Zacks Rank of 3 (Hold) [6] - Positive estimate revisions are interpreted as a good sign for the company's business outlook [5]